Immuneering (NASDAQ:IMRX) Issues Earnings Results

Immuneering (NASDAQ:IMRX) posted its earnings results on Friday. The company reported ($0.18) EPS for the quarter, FiscalAI reports.

Immuneering Trading Up 3.6%

NASDAQ:IMRX traded up $0.18 during mid-day trading on Friday, hitting $5.16. 381,209 shares of the company’s stock traded hands, compared to its average volume of 1,801,022. The firm has a 50 day moving average of $5.25 and a two-hundred day moving average of $6.07. The firm has a market capitalization of $333.18 million, a price-to-earnings ratio of -2.90 and a beta of 0.46. Immuneering has a 12 month low of $1.10 and a 12 month high of $10.08.

Analysts Set New Price Targets

IMRX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Immuneering in a research note on Thursday, November 13th. Finally, Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Insider Activity at Immuneering

In related news, Director Peter Feinberg purchased 20,000 shares of Immuneering stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $4.35 per share, with a total value of $87,000.00. Following the acquisition, the director directly owned 135,441 shares in the company, valued at approximately $589,168.35. This trade represents a 17.32% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Thomas J. Schall acquired 21,645 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were bought at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the acquisition, the director owned 74,530 shares in the company, valued at approximately $348,055.10. This trade represents a 40.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 51,819 shares of company stock valued at $234,472 over the last three months. 22.90% of the stock is owned by company insiders.

Institutional Trading of Immuneering

A number of hedge funds have recently modified their holdings of IMRX. Caitong International Asset Management Co. Ltd bought a new stake in shares of Immuneering during the fourth quarter valued at approximately $33,000. SummitTX Capital L.P. bought a new stake in Immuneering in the 4th quarter valued at $69,000. 683 Capital Management LLC bought a new position in shares of Immuneering during the 4th quarter worth about $992,000. Price T Rowe Associates Inc. MD boosted its position in shares of Immuneering by 10.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock valued at $13,121,000 after acquiring an additional 195,176 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Immuneering in the fourth quarter valued at about $607,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.